SCHEMBL16615992

SCHEMBL16615992

CC(C)OC(=O)c1ncnc(N2CCN(C(=O)OC(C)(C)C)CC2)c1[C@H](C)CC(=O)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KIT P10721 2/20 0.44
MAPT P10636 3/20 0.43
TLR9 Q9NR96 4/20 0.41
TLR7 Q9NYK1 2/20 0.41
ACHE P22303 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
BACE1 P56817 1/20 0.40
GPR119 Q8TDV5 2/20 0.39
MAPK1 P28482 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
NTSR1 P30989 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15390471 1.00 MEN1 (0.46) MEN1KMT2AKITMAPTTLR9
SCHEMBL29165621 0.92 MEN1 (0.49) MEN1KMT2AKITMAPTTLR9
SCHEMBL16616180 0.87 MEN1 (0.47) MEN1KMT2AKITMAPTTLR9
SCHEMBL16616178 0.87 MEN1 (0.47) MEN1KMT2AKITMAPTTLR9
SCHEMBL16624828 0.84 GABRP (0.34) MEN1KMT2AKITMAPTL3MBTL1
SCHEMBL25229763 0.81 MEN1 (0.47) MEN1KMT2AKITMAPTTLR9
SCHEMBL30466956 0.81 MEN1 (0.47) MEN1KMT2AKITMAPTTLR9
SCHEMBL30466960 0.81 MEN1 (0.47) MEN1KMT2AKITMAPTTLR9
SCHEMBL25277525 0.76 AKT1 (0.42) KMT2AMAPTMAPK1NPSR1
SCHEMBL25277524 0.76 AKT1 (0.42) KMT2AMAPTMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861583-B1 PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC (US) 2016-06-29 EP disclosed
EP-2861583-B1 PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS ARRAY BIOPHARMA INC (US) 2016-06-29 EP disclosed
US-9309204-B2 Process for making hydroxylated cyclopentylpyrimidine compounds ARRAY BIOPHARMA INC. (US) 2016-04-12 US disclosed
US-9309204-B2 Process for making hydroxylated cyclopentylpyrimidine compounds ARRAY BIOPHARMA INC. (US) 2016-04-12 US disclosed
US-9309204-B2 Process for making hydroxylated cyclopentylpyrimidine compounds ARRAY BIOPHARMA INC. (US) 2016-04-12 US disclosed
US-20150099881-A1 PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS GENETECH, INC. (US) 2015-04-09 US disclosed
US-20150099881-A1 PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS GENETECH, INC. (US) 2015-04-09 US disclosed
US-20150099881-A1 PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS GENETECH, INC. (US) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099881-A1 PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS PIK3CA, DHPS, PIK3CD MEN1 3736/4885KMT2A 2511/4885KIT 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.